MedPath

Post-marketing surveillance: Long term efficacy and safety of Valbenazine in patients with tardive dyskinesia

Not Applicable
Recruiting
Conditions
Tardive Dyskinesia
Registration Number
JPRN-UMIN000049606
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
500
Inclusion Criteria

Not provided

Exclusion Criteria

-Patients with a history of hypersensitivity to any in-gredients of this drug -Patients with long QT syndrome congenital or a history of Torsades de pointes [excessive QT interval prolongation, ventricular tachycardia (including Torsades de pointes) may occur.]

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath